New stock information | English Silicon Intelligence sprints to the Hong Kong Stock Exchange main board with the first AI innovative drug stock, having the fastest progressing AI-driven research and development project globally.

According to the Zhitong Finance APP, InSilico Medicine (hereinafter referred to as "English Silicon Intelligence") updated its prospectus on May 8, 2025, as they prepare to list on the Main Board of the Hong Kong Stock Exchange as the first AI innovative pharmaceutical company. Morgan Stanley, CICC, and GF Securities are serving as joint sponsors, and BNP Paribas is the global coordinator.